Investigating new treatments to enhance brain cell growth in Alzheimer's disease.
Official title: Preclinical characterization of splice-modifying antisense oligonucleotides targeting neurogenesis in human AD neural cells
Funded at Bolden Therapeutics, INC. · NIH-10922179 · Data updated 2026-11-12
This study is exploring a new treatment that uses special molecules to help brain cells grow and improve memory, which could be helpful for people with Alzheimer's disease.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bolden Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Providence, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $504,505 |
| NIH project number | 1R43AG084445-01A1 |
| Project ID | NIH-10922179 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults aged 21 and older who are experiencing mild cognitive impairment or early stages of Alzheimer's disease.
✕Less likely to help
Patients with advanced Alzheimer's disease or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on developing antisense oligonucleotides (ASOs) that can modify RNA splicing to enhance adult hippocampal neurogenesis, which is crucial for learning and memory. By using human neural cell cultures, the study aims to evaluate how these ASOs can improve cognitive function in the context of Alzheimer's disease. The approach involves testing these ASOs in patient-derived cell lines to assess their effectiveness in altering protein expression and signaling pathways related to neurogenesis. If successful, this research could lead to new therapeutic strategies for preventing or treating Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options to enhance cognitive function and slow the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise with antisense oligonucleotides in regulating RNA splicing, indicating potential for success in this novel application.
Where this research is happening
-
Bolden Therapeutics, INC.
Providence, United States Active
Researchers
- Principal investigator: Valat, Anne — Bolden Therapeutics, INC.
- Study coordinator: Valat, Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.